市場調査レポート

商品コード

1403452

結核診断市場の2030年までの予測：製品タイプ、検査タイプ、病期、エンドユーザー、地域別の世界分析

Tuberculosis Diagnostics Market Forecasts to 2030 - Global Analysis By Product Type, Test Type, Disease Stage, End User and By Geography

出版日: 2024年01月01日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 655,285円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 828,975円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 1,002,665円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,184,250円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.90円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の結核診断市場は2023年に20億7,000万米ドルを占め、予測期間中にCAGR 7.6％で成長し、2030年には34億6,000万米ドルに達すると予測されています。

結核は、結核菌によって引き起こされる伝染病であり、主に患者の肺、脊椎、脳を攻撃します。結核診断は、結核感染を客観的かつ正確に特定します。結核診断は、似たような症状を持つ他の呼吸器疾患と結核を区別するのに役立ち、誤診や不必要な治療を減らすことができます。

WHOの世界結核レポート2022によると、2021年には世界で約1,060万人が結核に罹患し、2020年に報告された1,010万人から4.5％増加しました。

薬剤耐性結核

多剤耐性結核（MDR-TB）や広範囲薬剤耐性結核（XDR-TB）といった薬剤耐性株の出現により、正確で迅速な診断検査が必要とされています。薬剤耐性結核菌は、標準的な第一選択抗結核薬に反応しないため、その発見と適切な治療が重要となっています。従来の診断法では薬剤耐性結核菌の同定が困難なため、治療が遅れたり、効果がなかったり、感染が拡大したり、患者の転帰が悪くなったりする可能性があります。その結果、薬剤耐性結核を正確に検出できる高度な診断法に対する需要が高まっています。

高コスト

分子検査や遺伝子型検査などの高度な診断技術は、喀痰塗抹顕微鏡検査のような伝統的な方法と比較して、高額な費用がかかることが多いです。これらの検査にかかる費用には、検査キットだけでなく、その実施に必要な機器、検査室のインフラ、熟練した人材も含まれます。そのため、高額なコストはヘルスケアプロバイダーがより高度で精密な診断技術を導入することを躊躇させ、市場の成長を阻害する可能性があります。

高度な診断技術

ポリメラーゼ連鎖反応（PCR）や核酸増幅検査（NAAT）などの分子技術の活用により、結核の検出感度が向上し、菌量が少ない症例でも診断が可能になった。さらに、ポイント・オブ・ケア検査の改善により、診断が患者により近いものとなった。これは、治療開始から結果が出るまでの時間が短縮されるため、資源が限られている環境では特に有利です。したがって、こうした高度な診断技術は市場の成長を加速させる。

スティグマ

感染様式に関する誤解、感染への恐怖、貧困や社会から疎外された集団との関連は、結核を取り巻くスティグマを助長する要因の一部です。しかし、このようなスティグマは、個人が症状を公表したり、ヘルスケアを受けたり、結核診断検査を受けたりすることに消極的になることにつながります。社会的排除や差別、社会的な好ましくない認識を恐れて、結核診断サービスを受けられない場合もあります。そのため、診断が先延ばしされ、病気の蔓延につながる可能性があります。このような要因が市場の需要を妨げています。

COVID-19の影響

COVID-19の大流行は結核診断市場に大きな影響を与えました。当初はヘルスケアシステムを混乱させ、結核診断からリソースを転換させたが、同時に強固な診断インフラの重要性を浮き彫りにしました。パンデミックが沈静化するにつれ、ヘルスケアシステム強化の必要性に対する認識が高まり、結核診断に長期的な利益がもたらされる可能性があります。さらに、COVID-19は遠隔医療とデジタルヘルスの進歩を加速させた可能性があり、結核診断の能力を向上させる可能性があります。

診断検査法セグメントは予測期間中最大となる見込み

診断検査法セグメントは最大のシェアを占めると推定されます。世界のほとんどの病院や診療所では、塗抹顕微鏡検査だけでなく培養ベースの検査も行われています。このため、より高度な診断手技を利用できない患者にとっては、結核診断の有力な選択肢となっています。さらに、核酸増幅検査（NAAT）のような新しい検査が広く利用されるようになってきているとはいえ、塗抹顕微鏡検査と培養に基づく検査は、結核を診断するための最も正確な検査であると考えられています。

予測期間中、喀痰塗抹顕微鏡検査分野のCAGRが最も高くなると予想されます。

喀痰塗抹顕微鏡検査分野は、予測期間中に有利な成長が見込まれます。喀痰塗抹顕微鏡検査は、喀痰サンプル中のAFB（Acid-Fast Bacilli：抗酸菌）を検出するために使用される簡便で費用対効果の高い技術であり、肺結核の診断に役立ちます。喀痰塗抹顕微鏡検査は、高度な検査インフラや高価な機器を必要としないため、資源が限られた環境でも広く利用できます。さらに、迅速な結果が得られるため、医療従事者は結核治療を速やかに開始することができ、感染を減らし、患者の転帰を改善することができます。

最大のシェアを占める地域

アジア太平洋地域は、その高い負担とこの疾患の急速な増殖により、市場を独占し、最大の市場シェアを占めています。この地域のいくつかの国で結核罹患率が上昇していることが、市場収益増加の主な要因の1つです。さらに、この地域の高い死亡率と低い人間開発指数は、市場収益の成長を支える重要な要因です。バングラデシュ、中国、インド、インドネシア、パキスタン、フィリピンは、この地域で影響を受けている国のひとつです。

CAGRが最も高い地域：

北米は、成人および小児の結核有病率の上昇により、予測期間中に有益な成長を遂げることが期待されています。この地域の医療研究機関では、病原体特異的代謝経路に関連する有益な発見が増えています。これは、病原体の免疫反応、細菌の増殖、または細菌の核酸増幅の検出に焦点を当てた既存の技術の代替となる可能性があります。さらに、AIとナノテクノロジーの組み合わせは、北米の患者の結核診断プロセスの改善に大きく役立ちます。

無料のカスタマイズ提供：

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかを受けることができます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Becton Dickinson and Company
Qiagen NV
Thermo Fisher Scientific Inc.
Oxford Immunotec Ltd.
Hoffmann-La Roche Ltd.
Hologic Inc.
BioMerieux SA
Akonni Biosystems Inc.
Cepheid Inc.
Alere Inc.
PAR Pharmaceuticals
Hain Life Science.
Lionex GmbH

図表

List of Tables

Table 1 Global Tuberculosis Diagnostics Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
Table 3 Global Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
Table 4 Global Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
Table 5 Global Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
Table 6 Global Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 7 Global Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 8 Global Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
Table 9 Global Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
Table 10 Global Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
Table 11 Global Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
Table 12 Global Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
Table 13 Global Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
Table 14 Global Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
Table 15 Global Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 16 Global Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
Table 17 Global Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
Table 18 Global Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
Table 19 Global Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 20 Global Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
Table 21 Global Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
Table 22 Global Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
Table 23 Global Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
Table 24 Global Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 25 North America Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
Table 26 North America Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
Table 27 North America Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
Table 28 North America Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
Table 29 North America Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
Table 30 North America Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 31 North America Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 32 North America Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
Table 33 North America Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
Table 34 North America Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
Table 35 North America Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
Table 36 North America Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
Table 37 North America Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
Table 38 North America Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
Table 39 North America Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 40 North America Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
Table 41 North America Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
Table 42 North America Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
Table 43 North America Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 44 North America Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
Table 45 North America Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
Table 46 North America Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
Table 47 North America Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
Table 48 North America Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 49 Europe Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
Table 50 Europe Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
Table 51 Europe Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
Table 52 Europe Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
Table 53 Europe Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
Table 54 Europe Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 55 Europe Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 56 Europe Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
Table 57 Europe Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
Table 58 Europe Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
Table 59 Europe Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
Table 60 Europe Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
Table 61 Europe Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
Table 62 Europe Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
Table 63 Europe Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 64 Europe Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
Table 65 Europe Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
Table 66 Europe Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
Table 67 Europe Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 68 Europe Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
Table 69 Europe Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
Table 70 Europe Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
Table 71 Europe Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
Table 72 Europe Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 73 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
Table 74 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
Table 75 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
Table 76 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
Table 77 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
Table 78 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 79 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 80 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
Table 81 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
Table 82 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
Table 83 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
Table 84 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
Table 85 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
Table 86 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
Table 87 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 88 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
Table 89 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
Table 90 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
Table 91 Asia Pacific Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 92 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
Table 93 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
Table 94 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
Table 95 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
Table 96 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 97 South America Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
Table 98 South America Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
Table 99 South America Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
Table 100 South America Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
Table 101 South America Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
Table 102 South America Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 103 South America Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 104 South America Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
Table 105 South America Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
Table 106 South America Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
Table 107 South America Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
Table 108 South America Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
Table 109 South America Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
Table 110 South America Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
Table 111 South America Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 112 South America Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
Table 113 South America Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
Table 114 South America Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
Table 115 South America Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 116 South America Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
Table 117 South America Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
Table 118 South America Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
Table 119 South America Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
Table 120 South America Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 121 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
Table 122 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
Table 123 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
Table 124 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
Table 125 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
Table 126 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 127 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 128 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
Table 129 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
Table 130 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
Table 131 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
Table 132 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
Table 133 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
Table 134 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
Table 135 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 136 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
Table 137 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
Table 138 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
Table 139 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 140 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2021-2030) ($MN)
Table 141 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
Table 142 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
Table 143 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
Table 144 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24677

According to Stratistics MRC, the Global Tuberculosis Diagnostics Market is accounted for $2.07 billion in 2023 and is expected to reach $3.46 billion by 2030 growing at a CAGR of 7.6% during the forecast period. Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis and it mainly attacks the lungs, spine, and brain of the patients. Tuberculosis diagnostics provide objective and precise identification of TB infection. They help differentiate TB from other respiratory diseases with similar symptoms, reducing misdiagnosis and unnecessary treatments.

According to the WHO Global Tuberculosis report 2022, in 2021, approximately 10.6 million individuals fell ill with tuberculosis globally, representing 4.5% rise from 10.1 million cases reported in 2020.

Market Dynamics:

Driver:

Drug-resistant TB

The emergence of drug-resistant strains, such as multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), has created a need for accurate and rapid diagnostic tests. Drug-resistant TB strains do not respond to the standard first-line anti TB medications, making their detection and appropriate treatment critical. Traditional diagnostic methods may not be effective in identifying drug-resistant strains, leading to delayed or ineffective treatment, increased transmission, and poor patient outcomes. As a result, there is a growing demand for advanced diagnostics that can accurately detect drug-resistant TB.

Restraint:

High cost

Advanced diagnostic technologies, such as molecular tests and genotypic assays, often come with a higher price tag compared to traditional methods like sputum smear microscopy. The cost of these tests includes not only the test kits but also the equipment, laboratory infrastructure, and skilled personnel required for their implementation. Therefore, high costs may deter healthcare providers from implementing more advanced and precise diagnostic techniques, impeding the growth of the market.

Opportunity:

Advanced diagnostic technologies

The utilization of molecular techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), allows for the detection of TB with enhanced sensitivity, enabling diagnosis even in cases with low bacterial loads. Additionally, improvements in point-of-care testing bring diagnostics closer to the patient. This is especially advantageous in settings with limited resources because it shortens the time between starting treatment and receiving results. Therefore, these advanced diagnostic technologies accelerate market growth.

Threat:

Stigma

Misconceptions regarding the mode of transmission, fear of infection, and associations with poverty or marginalized groups are some of the factors that contribute to the stigma surrounding tuberculosis. However, this stigma can lead to reluctance among individuals to disclose their symptoms, seek healthcare, or undergo TB diagnostic testing. People may be unable to receive TB diagnostic services because of fear of social exclusion, discrimination, or unfavourable societal perceptions. This can postpone diagnosis and contribute to the disease's spread. These factors hamper market demand.

COVID-19 Impact

The COVID-19 pandemic has had a significant impact on the tuberculosis diagnostics market. While it initially disrupted healthcare systems, diverting resources away from TB diagnostics, it also highlighted the importance of robust diagnostic infrastructure. Long-term benefits for TB diagnostics could result from increased awareness of the need for strengthening healthcare systems as the pandemic fades. Furthermore, COVID-19 may have accelerated advancements in telemedicine and digital health, which could improve the capacity for tuberculosis diagnosis.

The diagnostic laboratory methods segment is expected to be the largest during the forecast period

The diagnostic laboratory methods segment is estimated to hold the largest share. Most hospitals and clinics globally provide culture-based tests as well as smear microscopy. Due to this, they are a viable choice for tuberculosis diagnosis for patients who might not have access to more sophisticated diagnostic procedures. Moreover, while newer tests, such as nucleic acid amplification tests (NAATs), are becoming more widely available, smear microscopy and culture-based tests are still considered to be the most accurate tests for diagnosing tuberculosis.

The sputum smear microscopy segment is expected to have the highest CAGR during the forecast period

The sputum smear microscopy segment is anticipated to have lucrative growth during the forecast period. It is a simple and cost-effective technique used to detect acid-fast bacilli (AFB) in sputum samples, aiding in the diagnosis of pulmonary TB. Sputum smear microscopy is widely available, even in resource-limited settings, as it does not require sophisticated laboratory infrastructure or expensive equipment. Moreover, it provides rapid results, enabling healthcare providers to initiate TB treatment promptly, reducing transmission, and improving patient outcomes.

Region with largest share:

Asia Pacific dominated the market and accounted for the largest market share due to its high burden as well as the rapid proliferation of this disease. The rising rates of tuberculosis in several of the countries in this region are one of the primary drivers of the increase in market revenue. Furthermore, the high mortality rate and low human development index in this region are important factors that support the growth in market revenue. Bangladesh, China, India, Indonesia, Pakistan, and the Philippines are among the affected nations in this region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, owing to the rising prevalence of tuberculosis among adults and children. Medical research institutes in this region are discovering an increasing number of benefits associated with pathogen-specific metabolic pathways. This could serve as a substitute for the existing techniques that focus on the detection of pathogen immune responses, bacterial growth, or bacterial nucleic acid amplification. Additionally, AI and nanotechnology combined significantly aid in improving the tuberculosis diagnosis process among patients in North America.

Key players in the market:

Some of the key players in the Tuberculosis Diagnostics Market include Becton Dickinson and Company, Qiagen NV, Thermo Fisher Scientific Inc., Oxford Immunotec Ltd., Hoffmann-La Roche Ltd., Hologic Inc., BioMerieux SA, Akonni Biosystems Inc., Cepheid Inc., Alere Inc., PAR Pharmaceuticals, Hain Life Science and Lionex GmbH.

Key Developments:

In February 2022 - QIAGEN announced that its QuantiFERON tuberculosis testing solution received the approval of the fourth generation of a modern gold standard test in China.

In March 2022, Thermo Fisher Scientific Inc. launched the SeqStudio Flex Series Genetic Analyzer for research & development of infectious disease detection, which is expected to expand the company's product portfolio in the market.

Product Types Covered:

Sputum Smear Microscopy
Culture-Based Diagnostics
Rapid Molecular Diagnostics
Other Product Types

Test Types Covered:

Detection of Latent Infection
Radiographic Method
Nucleic Acid Testing
Phage Assay
Diagnostic Laboratory Methods
Detection of Drug Resistance
Cytokine Detection Assay
Other Test Types

Disease Stages Covered:

Active Tuberculosis
Latent Tuberculosis

End Users Covered:

Physician's Office Laboratories
Hospitals and Diagnostic Laboratories
Reference Laboratories
Academics and Research Facilities
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Tuberculosis Diagnostics Market, By Product Type

5.1 Introduction
5.2 Sputum Smear Microscopy
5.3 Culture-Based Diagnostics
5.4 Rapid Molecular Diagnostics
5.5 Other Product Types

6 Global Tuberculosis Diagnostics Market, By Test Type

6.1 Introduction
6.2 Detection of Latent Infection
6.3 Radiographic Method
6.4 Nucleic Acid Testing
6.5 Phage Assay
6.6 Diagnostic Laboratory Methods
6.7 Detection of Drug Resistance
6.8 Cytokine Detection Assay
6.9 Other Test Types

7 Global Tuberculosis Diagnostics Market, By Disease Stage

7.1 Introduction
7.2 Active Tuberculosis
7.3 Latent Tuberculosis

8 Global Tuberculosis Diagnostics Market, By End User

8.1 Introduction
8.2 Physician's Office Laboratories
8.3 Hospitals and Diagnostic Laboratories
8.4 Reference Laboratories
8.5 Academics and Research Facilities
8.6 Other End Users

9 Global Tuberculosis Diagnostics Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Becton Dickinson and Company
11.2 Qiagen NV
11.3 Thermo Fisher Scientific Inc.
11.4 Oxford Immunotec Ltd.
11.5 Hoffmann-La Roche Ltd.
11.6 Hologic Inc.
11.7 BioMerieux SA
11.8 Akonni Biosystems Inc.
11.9 Cepheid Inc.
11.10 Alere Inc.
11.11 PAR Pharmaceuticals
11.12 Hain Life Science.
11.13 Lionex GmbH